MeSH

A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system.

Year introduced: 1967

Cytoplasmic proteins that specifically bind glucocorticoids and mediate their cellular effects. The glucocorticoid receptor-glucocorticoid complex acts in the nucleus to induce transcription of DNA. Glucocorticoids were named for their actions on blood glucose concentration, but they have equally important effects on protein and fat metabolism. Cortisol is the most important example.

Year introduced: 1986(1977)

associated with changes in the transcriptional activity of anti-glucocorticoids and low concentrations of glucocorticoids; RefSeq NM_198169

Date introduced: September 29, 2004

associated with changes in the transcriptional activity of anti-glucocorticoids and low concentrations of glucocorticoids; RefSeq NM_031803

Date introduced: September 29, 2004

An enzyme that catalyzes the transfer of cytidylate (CMP) to choline phosphate to form CDPcholine. It is the rate-limiting enzyme in the choline pathway for the biosynthesis of phosphatidylcholine. Its activity is increased by glucocorticoids. EC 2.7.7.15.

Year introduced: 1998

A group of corticosteroids bearing a hydroxy group at the 11-position.

Year introduced: 1973(1972)

A serpin family member that binds to and transports GLUCOCORTICOIDS in the BLOOD.

Year introduced: 1965(1964)

A group of corticosteroids carrying hydroxy groups, usually in the 11- or 17-positions. They comprise the bulk of the corticosteroids used systemically. As they are relatively insoluble in water, salts of various esterified forms are often used for injections or solutions.

Year introduced: 1973(1972)

A topical glucocorticoid used in various DERMATOSES. It is absorbed through the skin, bound to plasma albumin, and may cause adrenal suppression. It is also administered as the valerate.

Year introduced: 1991(1980)

A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.

Year introduced: 1999(1966)

from Antrodia camphorata, exerts anti-inflammatory effect via mimicking glucocorticoids; structure in first source

Date introduced: October 21, 2011

enhances SPB212 responsiveness to glucocorticoids; amino acid sequence given in first source; GenBank L10405; do not confuse with N-protein (G-protein)

Date introduced: January 19, 1996

low-molecular wt polypeptide produced by fetal lung in response to glucocorticoids; exogenous cpd has been shown to accelerate lung maturation

Date introduced: February 25, 1985

isolated from neutrophils treated with glucocorticoids; 16,000 dalton fragment identified as glycosylation inhibitory factor; phospholipase inhibiting factor

Date introduced: August 21, 1981

intracellular polypeptide causing anti-phospholipase effect of glucocorticoids

Date introduced: January 7, 1981

supernantant factor produced by the interaction between glucocorticoids & human blood monocytes in culture; destroyed by proteolytic enzymes; MW 12,000 to 15,000

Date introduced: January 1, 1977

steroidal progestin with differential binding towards steroids receptors such as PR and glucocorticoids

Date introduced: November 17, 2020